Home・Akcijų sąrašas・Compugen Ltd

Compugen Ltd

Uždarymo kaina

2.6 -5.11

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

2.58

Max

2.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	663K -7M
Pardavimai	426K 2.6M
P/E Sektoriaus vid.	6.816 57.366
Pelnas, tenkantis vienai akcijai	-0.07
Pelno marža	-269.254
Darbuotojai	75
EBITDA	665K -7M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+92.31% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-09

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	20M 245M
Ankstesnė atidarymo kaina	7.71
Ankstesnė uždarymo kaina	2.6

Compugen Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-30 23:53; UTC

EUR/AUD is trading slightly higher in after-market hours, continuing its performance since Friday's close, though it remains near the lower end of its one-month range.

2026-08-30 23:53; UTC

Correlated Moves

Gold/AUD is lower amid cautious sentiment following Barclays' warning of a potential commodity shock due to adverse weather and underinvestment in production.

2026-08-30 23:53; UTC

Correlated Moves

Silver Ounce vs Euro is trading lower amid a broader decline in gold prices. Market sentiment is impacted by a Barclays report on potential commodity shocks.

2026-08-30 23:51; UTC

Correlated Moves

The S&P 500 Index is lower amid broader market trends and cautious investor sentiment following Barclays' forecasts of a potential commodity shock.

2026-08-30 23:51; UTC

Ethereum Drops 2.5% Amid Tech Stock Sell-Off and Economic Indicators, While Commodity Shock Looms from El Niño and Geopolitical Tensions Persist.

2026-08-30 23:51; UTC

Cryptocurrency Markets Decline Amid Geopolitical Tensions and Commodity Shock Warnings, with Key Economic Data Releases Ahead.

2026-08-30 23:51; UTC

Cryptocurrency markets decline as hedge funds sell tech stocks, while looming commodity shocks and geopolitical tensions raise inflation concerns ahead of key U.S. and Canadian labor data releases.

2026-08-30 23:51; UTC

Cryptocurrency markets decline as hedge funds sell tech stocks; Japan's economic indicators reveal consumer spending trends amid global uncertainties, while Barclays warns of a commodity shock from El Niño.

2026-08-30 23:51; UTC

Brazil's S&P Global Services PMI set for release on September 3, with analysts wary of further contraction following August's drop to 49.7 amid rising costs and political uncertainties.

2026-08-30 23:51; UTC

Australia's Building Permits Expected to Decline by 4.8% in July Amidst Economic Pressures and Market Volatility

2026-08-30 23:51; UTC

EUR/DKK remains effectively unchanged in after-market trading, showing unusual stability within a narrow band around its one-month trading range midpoint.

2026-08-30 23:51; UTC

Correlated Moves

Gold Ounce vs Euro is trading lower, continuing a five-session decline, influenced by falling Silver and cautious sentiment amid forecasts of a commodity shock.

2026-08-30 23:51; UTC

News

Bitcoin is trading lower today, despite earlier gains and social media discussions about Steak 'n Shake's Bitcoin initiative and potential AI investor interest.

2026-08-30 23:51; UTC

Bitcoin is trading lower during Sunday’s session amid heightened volatility. The price remains above its 20-day moving average and near its one-month range.

2026-08-30 23:42; UTC

Correlated Moves

The Nasdaq 100 Index is lower during Sunday’s session, reflecting broader market caution amid concerns over potential commodity shocks and adverse weather patterns.

2026-08-30 23:41; UTC

Japan's Industrial Production Expected to Decline in July Amid Global Economic Concerns and Commodity Supply Chain Disruptions.

2026-08-30 23:41; UTC

U.S. Unemployment Rate Release on September 4, 2026 Expected at 4.2%, Amid Cautious Optimism and Potential Fed Policy Implications

2026-08-30 23:41; UTC

US Average Hourly Earnings Expected to Rise 0.2% Amid Cautious Market Sentiment on Wage Growth and Inflation Concerns

2026-08-30 23:41; UTC

Labor Force Participation Rate in the U.S. Declines to 61.4%, Raising Concerns Ahead of September 2026 Data Release

2026-08-30 23:41; UTC

Investors Anticipate Key U.S. Average Hourly Earnings Data Amid Rising Inflation Concerns Ahead of September 4 Release

2026-08-30 23:41; UTC

US Non-Farm Payrolls Expected to Rise by Only 45K Jobs in August Amid Growing Employment Concerns

2026-08-30 23:41; UTC

Canada's Unemployment Rate Expected to Decrease Slightly to 6.4% Amidst Economic Challenges and Improved Employment Figures

2026-08-30 23:41; UTC

Canada's Labor Force Participation Rate Release on September 4, 2026, May Reflect Employment Dynamics Amid Housing Initiatives.

2026-08-30 23:41; UTC

Canada's Employment Change Forecast for August 2026 Predicts +15.8K Jobs Amid Positive Labor Market Sentiment Following July's Surprising Gain of +75.1K Positions

2026-08-30 23:41; UTC

Canada's Full-Time Employment Change Report Set for Release on September 4, Amid Economic Concerns and Political Developments.

2026-08-30 23:41; UTC

Canada's Part-Time Employment Change Report Set for September 4, 2026, Amid Cautious Optimism in Labor Market Dynamics.

2026-08-30 23:31; UTC

Correlated Moves

Avalanche is trading lower amid broader market sentiment, reflecting volatility. The asset remains above its 20-day moving average despite today's decline.

2026-08-30 23:31; UTC

Terra is trading lower today amid ongoing volatility and remains below its 20-day moving average, reflecting a decline since Saturday's session.

2026-08-30 23:31; UTC

Japan's Retail Sales Expected to Rise 0.03% YoY in July Amid Cautious Economic Sentiment and Weak Bond Market Performance

2026-08-30 23:31; UTC

Correlated Moves

XRP is declining during Sunday’s session amid notable volatility, aligning with a drop in Bitcoin. The asset remains above its 20-day moving average.

Akcijų palyginimas

Kainos pokytis

Compugen Ltd Prognozė

Kainos tikslas

By TipRanks

92.31% į viršų

12 mėnesių prognozė

Vidutinis 5 USD 92.31%

Aukščiausias 6 USD

Žemiausias 4 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Compugen Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

Pirkti

Laikyti

Parduoti

Remiantis 2 analitikų, pateikusių Compugen Ltd akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Compugen Ltd

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.